Small Stocks, Big Money™

Sharps Technology (Nasdaq: STSS) signed a transformative five-year, $50 million sales agreement with a leading U.S. medical supplier. This deal fully sells out the 10mL SoloGard syringe production capacity at Sharps' EU facility, prompting plans for expansion. The partnership addresses U.S. demand for non-Chinese syringes following FDA recalls and tariffs. With production commencing in Q4 2024, the agreement covers 500 million syringes, underscoring Sharps' commitment to innovative, high-quality medical devices and driving the company's growth in the U.S. healthcare market.

SolarMax Technology (Nasdaq: SMXT) plans to introduce engineering, procurement, and construction (EPC) services for large-scale solar and EV charging projects in the U.S. The company has signed a non-binding memorandum of understanding for a major commercial solar installation in Las Vegas, featuring a 4.27 MW solar power plant, a 2.0 MW energy storage system, and 10 EV charging stations. This move marks a significant milestone in SolarMax's strategy to leverage its international expertise in the burgeoning U.S. solar market, which is projected to reach $125 billion by 2030.

60 Degrees Pharmaceuticals (Nasdaq: SXTP) was awarded a contract by the U.S. Army Medical Materiel Development Activity to support the commercial validation of new packaging for ARAKODA® (tafenoquine), its FDA-approved malaria prevention drug. Anticipating increased sales in 2024, the company expanded the commercial batch size in Q1, resulting in a 515% year-over-year revenue increase. CEO Geoff Dow emphasized the importance of this support in maintaining a sustainable ARAKODA supply for both civilian and military users, with future potential in treating babesiosis.

Spectaire Holdings (Nasdaq: SPEC) has begun delivering AireCore units to a major energy industry customer, marking the start of a significant contract with $5 million annual recurring revenue potential. Combined with other recent orders, this could bring Spectaire to positive cash flow. AireCore’s cutting-edge micro mass spectrometer technology allows for precise, in-field emissions sampling and mandatory reporting. CEO Brian Semkiw highlighted the company's commitment to supporting clients in reducing Scope 1 emissions, leveraging a subscription-based model to ensure ongoing compliance and sustainability. The air quality monitoring market, valued at $5 billion in 2021, continues to grow, positioning Spectaire for substantial market opportunities.